ARTICLE | Clinical News

ZS Pharma jumps on ZS-9 Phase III data

September 24, 2014 2:05 AM UTC

ZS Pharma Inc. (NASDAQ:ZSPH) gained $3.69 (11%) to $38.05 on Tuesday after announcing positive Phase III data for lead candidate ZS-9 sodium zirconium cyclosilicate for hyperkalemia.

Preliminary results from the HARMONIZE trial (ZS004) showed all three dose levels of once-daily ZS-9 (5, 10 and 15 g) met the primary endpoint of preventing hyperkalemia recurrence compared with placebo over a 28-day treatment cycle. Last year, ZS-9 met the primary endpoint of reducing serum potassium levels from baseline to 48 hours vs. placebo in the Phase III ZS-003 trial to treat hyperkalemia. ...